Introduction
the pathological process of the disease.
Boswellia serrata (BS) (Family: Bursaraceae) known as Gaja-bhaksha (implying its ingestion by elephants) in Sanskrit and Sallaki Guggul in Ayurveda is widely used in India. BS gum has been mentioned in the ancient Indian Ayurvedic texts.
[1,2] Gum resin extracted from BS possesses good anti inflammatory, anti-arthritic and analgesic activities.
[3] It has been claimed to decrease the degradation of glycosaminoglycans thereby helping to prevent the destruction of articular cartilage.
[4] The efficacy and safety of BS in OA knee was studied in a randomized, double blind, placebo-controlled trial where BS was reported to be significantly better than placebo in relieving the symptoms of OA. [5] No comparative clinical trial is yet reported with BS. Hence, this study was planned to compare the efficacy, safety and tolerability of BS in OA knee with valdecoxib, a selective COX-2 inhibitor.
to the criteria of American College of Rheumatology [6] were recruited from the OPD of Kayachikitsa Government Ayurved College, Nagpur. The diagnosis was based on clinical presentation and X-ray findings and confirmed by the orthopedician. Patients were enrolled between December 2003 and May 2004 and were followed up to 7 months. Patients with history of peptic ulcer, acid peptic disease, concurrent illness, receiving concomitant drug therapy, having history of any drug allergy, having received corticosteroids within four weeks or any anti-inflammatory analgesic three days prior to enrolment, pregnant/lactating women were excluded. Informed, written consent was obtained from those who agreed to participate. Routine hematological investigations were done. The patients were assessed by Western Ontario and McMaster Universities OA index (WOMAC) scale (version VA 3.1) in which decrease in scores suggests improvement [7] and antero-posterior radiographs of affected knee joint in full extension. 
Sontakke et al.: Boswellia serrata extract compared to valdecoxib in osteoarthritis
The patients were randomly allocated by SAS system for Windows to two groups of 33 each to receive either Boswellia serrata extract (BSE) (Cap Wokvel TM , manufactured by Pharmanza India) each containing 333 mg of BSE thrice daily (BSE Group) or valdecoxib 10 mg (Tab Valdone, Cadila Pharmaceuticals Limited) once daily (Valdecoxib Group) for six months. The medicines were given orally and the patients were advised to take them after meals. Asking the patients to bring back the empty blister packs during each visit checked the compliance and the consumed drug count was measured. Consumption of 90% of the drug was considered as adequate compliance. None of the patients became pregnant during the trial period. The age reason given by all dropouts from valdecoxib group was that symptoms recurred if the patient missed a dose or two.
The basal WOMAC scores for pain, stiffness and difficulty in performing daily activities were compared with the scores at the end of each month. In BSE group, the difference in WOMAC scores was not statistically significant at the end of first month of intervention when compared to baseline (P>0.05). But from second month onwards the decrease was highly significant (P<0.001) as compared to the baseline and remained so throughout the intervention and even one month after the stoppage of the treatment [ Table 1 ].
Six patients from valdecoxib group and seven from BSE group of study subjects was above 40 years so chances of a group required rescue medication -tablet Ibuprofen 400 mg patient becoming pregnant were minimal. No advice about thrice daily, which was administered till symptomatic contraception was given. The BSE capsule contained the improvement. standardized extract of BS gum having minimum 40% total
In valdecoxib group, the decrease in WOMAC scores was boswellic acids (BA). The main components of BA in BSE used statistically significant at the end of one month of treatment were 11-keto-beta BA -6.44%, 3-O-Acetyl-beta BA-8.58%, alpha as compared to baseline (P<0.001) and persisted as long as BA -6.93% and 3-O-acetyl alpha BA-1.853%. The patients were the treatment was continued. One month after stopping the assessed by WOMAC scale at monthly intervals and at the end of treatment, the difference was not statistically significant study. Radiograph of the affected knee joint was repeated at the [ Table 1 ]. Basal WOMAC scores were comparable in the two end of study. The patients were under the assigned intervention treatment groups. The difference in WOMAC scores between for 30 days at a time and permitted to continue physiotherapy the two treatment groups was statistically significant at the they were receiving and advised to report ADRs. The drug end of one month for all the three symptoms. The WOMAC intervention was for a period of six months and assessment scores with BSE were significantly lower (P<0.001) than with done with WOMAC scale, was repeated at the end of seventh valdecoxib at the end of 7 months for all the three parameters. month to evaluate the residual effect of treatment.
There was no difference in the pre-and post-drug WOMAC scores in each group at monthly interval were radiographs of the affected knee joint. Three patients from compared with the basal scores by repeated measures ANOVA BSE group and two from valdecoxib group complained of followed by Dunnett's test. Between group comparison was acidity. They responded to treatment with tablet ranitidine done by unpaired 't' test and 'P' value less than 0.05 was 150 mg twice daily for seven days and chose to continue with considered statistically significant. the trial. Demographic characteristics of both groups were
In the BSE treated group the WOMAC scores did not show comparable. Two patients from BSE group and six from any significant decrease after the first month of intervention valdecoxib group dropped out from the study. From BSE group, but from second month onwards became significantly lower one patient dropped due to diarrhea and abdominal cramps as compared to the baseline and continued to be significantly and the other due to inadequate control of symptoms. The lower till one month after stopping the treatment. This indicates
Comparison of WOMAC scores in the two treatment groups at different time intervals that BSE has slower onset of action and takes more than a month for the action to manifest. At the same time its effect was persistent even after one month of stoppage of treatment. This is a valuable finding as most of the currently used drugs in OA from modern medicine provide short-lasting symptomatic relief, as also seen by us in the valdecoxib group, where the onset of action was fast but waned rapidly on stoppage of the treatment. Studies report that BSE prevented the degradation of articular cartilage, [5] which could be one of the mechanisms in arresting the progression of OA. A possible reason of the persistent effect of BSE even one month after stopping treatment may be an effect on the underlying pathology in OA. This is a valdecoxib in our study but the recent reports of valdecoxib producing serious cardiovascular and dermatological toxicity are of concern. [12, 13] We included valdecoxib as a comparator drug because at the time of protocol submission it was the latest drug on the scene, which was being widely prescribed for OA. However, subsequently it has been banned in India due to serious ADRs.
Thus, in terms of safety, efficacy and duration of action, the present study shows that BSE was superior to valdecoxib, except for the slower onset of action compared to valdecoxib.
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